Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating the long-term benefits of hydroxyurea in pediatric sickle cell anemia

16 Apr 2025

Abstract excerpt

ABSTRACT: Hydroxyurea is the primary disease-modifying medication for sickle cell anemia (SCA), but its long-term effects, particularly how these effects change over time, are not well understood. This study aimed to quantify the effects of hydroxyurea on clinical and laboratory outcomes in children with SCA over a prolonged period of use. We conducted a quasi-experimental study using contemporary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Hemoglobinopathies and Related Disorders
Share to Iron Metabolism and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40238672
DOI: 10.1182/bloodadvances.2024015564

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating the long-term benefits of hydroxyurea in pediatric sickle cell anemiaPMID 40238672Read ↗

Genotype Differences and Hydroxyurea Utilization Among Adults With Moderate to Severe Sickle Cell Disease.Semantic proximity Read ↗

Hydroxyurea in the sickle cell disease modern eraSemantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension studySemantic proximity Read ↗

Hydroxyurea for Children and Adults with Hemoglobin SC DiseaseSemantic proximity Read ↗

Fixed Low-Dose Hydroxyurea Therapy: A Strategy for Reducing Emergency Room Visits and Improving Treatment Adherence in Paediatric Sickle Cell Anaemia in Resource-Limited SettingsSemantic proximity Read ↗

Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.Semantic proximity Read ↗

Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan AfricaSemantic proximity Read ↗

Effects of hydroxyurea treatment for patients with hemoglobin SC diseaseSemantic proximity Read ↗

Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.Semantic proximity Read ↗

Economic Burden and Clinical Effectiveness of Different Hydroxyurea Dosing Regimens in Sickle Cell Disease: Evidence from NepalSemantic proximity Read ↗

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.